DK2463305T3 - Antistoffer mod OX-2/CD200 og anvendelser deraf - Google Patents
Antistoffer mod OX-2/CD200 og anvendelser deraf Download PDFInfo
- Publication number
- DK2463305T3 DK2463305T3 DK11005097.8T DK11005097T DK2463305T3 DK 2463305 T3 DK2463305 T3 DK 2463305T3 DK 11005097 T DK11005097 T DK 11005097T DK 2463305 T3 DK2463305 T3 DK 2463305T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- antibody
- val
- seq
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
Claims (18)
1. Farmaceutisk sammensætning, der omfatter et farmaceutisk acceptabelt bæremiddel og en effektiv mængde af et anti-CD200-antistof, hvor anti-CD200-antistoffet: (i) hæmmer interaktionen mellem CD200 og CD200R; og (ii) omfatter en variant Fc-konstant region, som: (a) er en variant Fc-konstant region, hvor CH1- og hængselregionen stammer fra human IgG2, og CH2- og CH3-regionerne stammer fra human IgG4; (b) omfatter den ene eller begge af: (A) en phenylalanin-til- alanin-substitution i position 234 og (B) en leucin-til-alanin-substitution i position 235 ifølge EU-indekset; (c) omfatter en K322A-mutation i CH2-domænet ifølge EU-indekset; eller (d) mangler en hængselregion.
2. Farmaceutisk sammensætning ifølge krav 1, hvor anti-CD200-antistoffet er et murint antistof, et kimærisk antistof, et humaniseret antistof, et deimmuniseret antistof eller et humant antistof.
3. Farmaceutisk sammensætning ifølge krav 1, hvor anti-CD200-antistoffet omfatter: I. (a) et let kæde-polypeptid, der omfatter: (i) aminosyreresterne 21 til 127 af SEQ ID NO: 24; eller (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 24; og (b) et tung kæde-polypeptid, der omfatter: (iii) aminosyreresterne 21 til 137 af SEQ ID NO: 15; eller (iv) aminosyreresterne 21 til 463 af SEQ ID NO: 15; II. (a) et let kæde-polypeptid, der omfatter: (i) aminosyreresterne 21 til 127 af SEQ ID NO: 32; eller (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 32; og (b) et tung kæde-polypeptid, der omfatter: (iii) aminosyreresterne 21 til 142 af SEQ ID NO: 20; Ill . (a) et let kæde-polypeptid, der omfatter: (i) aminosyreresterne 23 til 129 af SEQ ID NO: 28; eller (ii) aminosyreresterne 23 til 236 af SEQ ID NO: 28; og (b) et tung kæde-polypeptid, der omfatter: (iii) aminosyreresterne 20 til 136 af SEQ ID NO: 13; eller (iv) aminosyreresterne 20 til 462 af SEQ ID NO: 13; eller IV. (a) et tung kæde-polypeptid, der omfatter: (i) aminosyreresterne 20 til 136 af SEQ ID NO: 11; eller (ii) aminosyreresterne 20 til 136 af SEQ ID NO: 9; og (b) et let kæde-polypeptid, der omfatter aminosyreresterne 23 til 129 af SEQ ID NO: 26.
4. Farmaceutisk sammensætning ifølge krav 1, hvor den variante Fc-konstante region har nul ADCC- eller CDC-aktivitet.
5. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1-4 til anvendelse til behandling af cancer.
6. Farmaceutisk sammensætning til anvendelse ifølge krav 5, hvor canceren omfatter cancerceller, der udtrykker CD200.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor cancercellerne overudtrykker CD200 i forhold til normale celler af samme histologiske type som de celler, hvorfra cancercellerne er afledt.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 7, hvor canceren er udvalgt fra gruppen, der består af crista neuralis-cellecancer, plasmacellecancer, lymfom, leukæmi, ovariecancer, hudcancer, lungecancer, nyrecancer, brystcancer, prostatacancer, neuroblastom og myelom.
9. Anti-CD200-antistof til anvendelse til behandling af cancer, hvor anti-CD200-antistoffet: (i) hæmmer interaktionen mellem CD200 og CD200R; og (ii) omfatter en variant Fc-konstant region, som: (a) er en variant Fc-konstant region, hvor CH1- og hængselregionen stammer fra human IgG2, og CH2- og CH3-regionerne stammer fra human IgG4; (b) omfatter den ene eller begge af: (A) en phenylalanin-til- alanin-substitution i position 234 og (B) en leucin-til-alanin-substitution i position 235 ifølge EU-indekset; (c) omfatter en K322A-mutation i CH2-domænet ifølge EU-indekset; eller (d) mangler en hængselregion.
10. Anti-CD200-antistof ifølge krav 9 til anvendelse ifølge krav 9, hvor anti-CD200-antistoffet er et murint antistof, et kimærisk antistof, et humaniseret antistof, et deimmuniseret antistof eller et humant antistof.
11. Anti-CD200-antistof ifølge krav 9 til anvendelse ifølge krav 9, hvor anti-CD200-antistoffet omfatter: I. (a) et let kæde-polypeptid, der omfatter: (i) aminosyreresterne 21 til 127 af SEQ ID NO: 24; eller (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 24; og (b) et tung kæde-polypeptid, der omfatter: (iii) aminosyreresterne 21 til 137 af SEQ ID NO: 15; eller (iv) aminosyreresterne 21 til 463 af SEQ ID NO: 15; II. (a) et let kæde-polypeptid, der omfatter: (i) aminosyreresterne 21 til 127 af SEQ ID NO: 32; eller (ii) aminosyreresterne 21 til 234 af SEQ ID NO: 32; og (b) et tung kæde-polypeptid, der omfatter: (iii) aminosyreresterne 21 til 142 af SEQ ID NO: 20; III. (a) et let kæde-polypeptid, der omfatter: (i) aminosyreresterne 23 til 129 af SEQ ID NO: 28; eller (ii) aminosyreresterne 23 til 236 af SEQ ID NO: 28; og (b) et tung kæde-polypeptid, der omfatter: (iii) aminosyreresterne 20 til 136 af SEQ ID NO: 13; eller (iv) aminosyreresterne 20 til 462 af SEQ ID NO: 13; eller IV. (a) et tung kæde-polypeptid, der omfatter: (i) aminosyreresterne 20 til 136 af SEQ I D NO: 11; eller (ii) aminosyreresterne 20 til 136 af SEQ ID NO: 9; og (b) et let kæde-polypeptid, der omfatter aminosyreresterne 23 til 129 af SEQ ID NO: 26.
12. Anti-CD200-antistof ifølge krav 9 til anvendelse ifølge krav 9, hvor den variante Fc-konstante region har nul ADCC-eller CDC-aktivitet.
13. Anti-CD200-antistof ifølge et hvilket som helst af kravene 9-12 til anvendelse ifølge et hvilket som helst af kravene 9-12, hvor canceren omfatter cancerceller, der udtrykker CD200.
14. Anti-CD200-antistof ifølge krav 13 til anvendelse ifølge krav 13, hvor cancercellerne overudtrykker CD200 i forhold til normale celler af samme histologiske type som de celler, hvorfra cancercellerne er afledt.
15. Anti-CD200-antistof ifølge et hvilket som helst af kravene 9-14 til anvendelse ifølge et hvilket som helst af kravene 9-14, hvor canceren er udvalgt fra gruppen, der består af crista neuralis-cellecancer, plasmacellecancer, lymfom, leukæmi, ovariecancer, hudcancer, lungecancer, nyrecancer, brystcancer, prostatacancer, neuroblastom og myelom.
16. Anti-CD200-antistof ifølge et hvilket som helst af kravene 9-15 til anvendelse ifølge et hvilket som helst af kravene 9-15, hvor patienten skal have administreret et andet middel eller en terapi.
17. Anti-CD200-antistof ifølge krav 16 til anvendelse ifølge krav 16, hvor det andet middel er et kemoterapeutisk middel.
18. Anti-CD200-antistof ifølge krav 16 til anvendelse ifølge krav 16, hvor terapien er strålebehandling.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75842606P | 2006-01-12 | 2006-01-12 | |
| US75908506P | 2006-01-12 | 2006-01-12 | |
| US80199106P | 2006-05-18 | 2006-05-18 | |
| EP07716538A EP1984403A2 (en) | 2006-01-12 | 2007-01-11 | Antibodies to ox-2/cd200 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2463305T3 true DK2463305T3 (da) | 2016-08-29 |
Family
ID=38068567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11005097.8T DK2463305T3 (da) | 2006-01-12 | 2007-01-11 | Antistoffer mod OX-2/CD200 og anvendelser deraf |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8075884B2 (da) |
| EP (3) | EP3101033B1 (da) |
| JP (3) | JP5404052B2 (da) |
| KR (2) | KR20140091765A (da) |
| CN (1) | CN103690947A (da) |
| AU (1) | AU2007207764B2 (da) |
| BR (1) | BRPI0707126A2 (da) |
| CA (1) | CA2636577C (da) |
| DK (1) | DK2463305T3 (da) |
| ES (2) | ES2586825T3 (da) |
| HU (1) | HUE028179T2 (da) |
| IL (1) | IL192668A (da) |
| MX (1) | MX2008009015A (da) |
| NZ (2) | NZ599035A (da) |
| PL (1) | PL2463305T3 (da) |
| PT (1) | PT2463305T (da) |
| RU (2) | RU2520088C2 (da) |
| SG (2) | SG10201400426XA (da) |
| SI (1) | SI2463305T1 (da) |
| TW (1) | TW200804422A (da) |
| WO (1) | WO2007084321A2 (da) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US9249229B2 (en) | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7427665B2 (en) | 2000-12-08 | 2008-09-23 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line |
| NZ599035A (en) | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| DK2006381T3 (da) * | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | Fremgangsmåde til regulering af antistoffers blodfarmakokinetik |
| AU2007255753B2 (en) | 2006-06-08 | 2013-01-17 | Chugai Seiyaku Kabushiki Kaisha | Preventive or remedy for inflammatory disease |
| EP2121015A4 (en) * | 2007-01-11 | 2010-03-24 | Boehringer Ingelheim Int | CD200 AND ITS RECEIVER, CD200R, MODULE THE BONE MASS VIA THE DIFFERENTIATION OF OSTEOCLASTS |
| WO2009004339A2 (en) * | 2007-07-03 | 2009-01-08 | Imperial Innovations Limited | Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection |
| KR20100041849A (ko) * | 2007-07-25 | 2010-04-22 | 알렉시온 파마슈티칼스, 인코포레이티드 | Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도 |
| KR20100036362A (ko) | 2007-07-25 | 2010-04-07 | 알렉시온 파마슈티칼스, 인코포레이티드 | 자가면역 질환 치료 방법 및 조성물 |
| HUE029635T2 (en) | 2007-09-26 | 2017-03-28 | Chugai Pharmaceutical Co Ltd | A method for modifying an isoelectric point of an antibody by amino acid substitution in CDR |
| SG193868A1 (en) | 2007-09-26 | 2013-10-30 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
| KR20210022148A (ko) * | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
| KR101643005B1 (ko) | 2007-12-05 | 2016-07-28 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| US8206897B2 (en) | 2008-04-04 | 2012-06-26 | Trillium Therapeutics Inc. | Assay for soluble CD200 |
| CN101592668B (zh) * | 2008-05-31 | 2012-10-24 | 刘秀梅 | 定量测定植物中草药提取成分中雌二醇含量的方法 |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| MX2012008108A (es) * | 2010-01-11 | 2012-10-03 | Alexion Pharma Inc | Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200. |
| SG182823A1 (en) * | 2010-02-11 | 2012-09-27 | Alexion Pharma Inc | Therapeutic methods using an ti-cd200 antibodies |
| PT2663579T (pt) | 2011-01-14 | 2017-07-28 | Univ California | Terapêutica de anticorpos contra a proteína r0r-1 e métodos para sua utilização |
| JP6150734B2 (ja) * | 2011-02-03 | 2017-06-21 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用 |
| DK3006464T3 (da) | 2011-06-10 | 2018-09-17 | Canada Minister Nat Defence | Antiricin-antistoffer og anvendelser dera |
| EP3626739A1 (en) | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US9737598B2 (en) | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| EP3699198A1 (en) | 2014-11-17 | 2020-08-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| EP3250588A1 (en) | 2015-01-29 | 2017-12-06 | Board of Trustees of Michigan State University | Cryptic polypeptides and uses thereof |
| CA2981312C (en) | 2015-03-30 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| TWI738648B (zh) | 2015-04-14 | 2021-09-11 | 日商中外製藥股份有限公司 | 含有ｉｌ－３１拮抗劑作為有效成分之異位性皮膚炎的預防用及／或治療用醫藥組合物 |
| EP3294334B1 (en) | 2015-05-11 | 2020-07-08 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
| WO2017072310A1 (en) * | 2015-10-30 | 2017-05-04 | Medimmune Limited | Prevention of n-terminal truncation in igg light chains |
| CA3004048A1 (en) | 2015-11-03 | 2017-05-11 | Regents Of The University Of Minnesota | Cd200 inhibitors and methods of use thereof |
| WO2017220990A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 antibodies |
| WO2018075408A1 (en) | 2016-10-17 | 2018-04-26 | Alexion Pharmaceuticals, Inc. | Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin |
| WO2018102594A1 (en) | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
| WO2019067499A1 (en) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | BIOMARKER SIGNATURE FOR PREDICTING A TUMOR RESPONSE TO ANTI-CD200 THERAPY |
| WO2019126536A1 (en) * | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| US20210087267A1 (en) | 2017-12-20 | 2021-03-25 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| CN110357962B (zh) * | 2018-07-06 | 2021-11-26 | 北京天成新脉生物技术有限公司 | 低adcc/cdc功能性单抗及其制备方法与应用 |
| JP2021535142A (ja) | 2018-08-31 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略 |
| AR116668A1 (es) * | 2018-09-14 | 2021-06-02 | Lilly Co Eli | Anticuerpos agonistas contra cd200r y sus usos |
| US20220098310A1 (en) | 2018-12-06 | 2022-03-31 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
| JP2022518262A (ja) * | 2019-01-24 | 2022-03-14 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド | ナチュラルキラー細胞を刺激するための組成物及び方法 |
| KR20200099807A (ko) * | 2019-02-15 | 2020-08-25 | 아주대학교산학협력단 | 항체의 불변부위로만 구성된 항체 단편 및 이의 용도 |
| BR112022006590A2 (pt) | 2019-11-20 | 2022-06-28 | Chugai Pharmaceutical Co Ltd | Preparação contendo anticorpos |
| WO2022150740A1 (en) * | 2021-01-11 | 2022-07-14 | Board Of Regents, The University Of Texas System | Cross-reactive antibodies recognizing the coronavirus spike s2 domain |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| GB202303291D0 (en) * | 2023-03-07 | 2023-04-19 | Secr Defence | Medicament and medicament combination for use in the treatment of infectious disease |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| DE3307869A1 (de) | 1983-03-05 | 1984-09-06 | Dragoco Gerberding & Co Gmbh, 3450 Holzminden | Methylsubstituierte 1-((3-methylthio)-1-oxo-butyl)-cyclohex-2-ene, verfahren zu deren herstellung und deren verwendung als riech- und aromastoffe |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4634666A (en) | 1984-01-06 | 1987-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | Human-murine hybridoma fusion partner |
| EP0170697B1 (en) | 1984-02-08 | 1991-10-23 | Cetus Oncology Corporation | Toxin conjugates |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5092885A (en) | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
| EP0349578B2 (en) | 1987-03-02 | 1998-10-28 | Enzon Labs Inc. | Organism carrying a Single Chain Antibody Domain at its surface. |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| JPH0246297A (ja) | 1988-08-08 | 1990-02-15 | Takeda Chem Ind Ltd | モノクローナル抗体、抗体産生ハイブリドーマおよび抗体の製造法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| US20040010810A1 (en) | 1990-01-12 | 2004-01-15 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0470569B1 (en) | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DK0814159T3 (da) | 1990-08-29 | 2005-10-24 | Genpharm Int | Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5612205A (en) | 1990-08-29 | 1997-03-18 | Genpharm International, Incorporated | Homologous recombination in mammalian cells |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| WO1992012717A2 (en) | 1991-01-15 | 1992-08-06 | A composition containing a tetracycline and use for inhibiting angiogenesis | |
| DK1279731T3 (da) | 1991-03-01 | 2007-09-24 | Dyax Corp | Fremgangsmåde til udvikling af bindende miniproteiner |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| DE69226871T3 (de) | 1991-06-27 | 2009-09-24 | Bristol-Myers Squibb Co. | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5728815A (en) | 1992-03-30 | 1998-03-17 | Board Of Regents, The University Of Texas System | Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis |
| AU4541093A (en) | 1992-06-18 | 1994-01-24 | Genpharm International, Inc. | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| CA2140638C (en) | 1992-07-24 | 2010-05-04 | Raju Kucherlapati | Generation of xenogeneic antibodies |
| US5508717A (en) | 1992-07-28 | 1996-04-16 | Sony Corporation | Computer pointing device with dynamic sensitivity |
| US6228879B1 (en) | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| US6335160B1 (en) * | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US20050287630A1 (en) | 1995-04-27 | 2005-12-29 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| DK0859841T3 (da) | 1995-08-18 | 2002-09-09 | Morphosys Ag | Protein/(poly)peptidbiblioteker |
| CZ117798A3 (cs) | 1995-10-23 | 1998-08-12 | The Children's Medical Center Corporation | Antiangiogenní kompozice a způsoby léčby |
| EP0858506A4 (en) | 1995-10-31 | 2004-12-08 | Uab Research Foundation | GENETIC INDUCTION OF RECEPTORS TO TARGETED RADIOTHERAPY |
| WO1997021450A1 (en) | 1995-12-08 | 1997-06-19 | Brigham And Women's Hospital, Inc. | Ox-2 costimulatory molecule |
| US6465431B1 (en) | 1999-11-17 | 2002-10-15 | Boston Life Sciences, Inc. | Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis |
| AU710998B2 (en) | 1996-03-20 | 1999-10-07 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith |
| AU733303C (en) | 1996-05-31 | 2002-08-08 | Scripps Research Institute, The | Methods and compositions useful for inhibition of angiogenesis |
| CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| US6573256B2 (en) | 1996-12-30 | 2003-06-03 | Bone Care International, Inc. | Method of inhibiting angiogenesis using active vitamin D analogues |
| US6011138A (en) | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| US7223729B2 (en) | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| DE69833779T2 (de) | 1997-11-07 | 2006-11-30 | Trillium Therapeutics Inc., Toronto | Verfahren und zusammensetzungen zur immunomodulation |
| US6475784B1 (en) | 1997-11-14 | 2002-11-05 | Valentis, Inc. | Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides |
| AU1690399A (en) | 1997-12-26 | 1999-07-19 | Mochida Pharmaceutical Co., Ltd. | Neovascularization inhibitor containing dienogest as the active ingredient |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| WO1999058126A1 (en) | 1998-05-11 | 1999-11-18 | The Endowment For Research In Human Biology, Inc. | Use of neomycin for treating angiogenesis-related diseases |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| WO2000002902A1 (en) | 1998-07-13 | 2000-01-20 | Gill Parkash S | Novel inhibitors of angiogenesis and tumor growth |
| AU751283B2 (en) | 1998-07-14 | 2002-08-08 | Bristol-Myers Squibb Company | Lysine binding fragments of angiostatin |
| WO2000010507A2 (en) | 1998-08-21 | 2000-03-02 | The Children's Medical Center Corporation | Use of melanin for inhibition of angiogenesis and macular degeneration |
| US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
| JP2002534959A (ja) | 1998-12-08 | 2002-10-22 | バイオベーション リミテッド | 免疫原性タンパク質の改変方法 |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US20020192215A1 (en) | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
| WO2001046110A2 (en) | 1999-12-23 | 2001-06-28 | The University Of Georgia Research Foundation, Inc. | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| AU2001242159B2 (en) | 2000-03-17 | 2006-04-27 | Trillium Therapeutics Inc. | Methods and compositions for immunoregulation |
| CA2404528A1 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
| US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| WO2002011762A2 (en) | 2000-08-03 | 2002-02-14 | Gorczynski Reginald M | Methods and compositions for modulating tumor growth |
| US20030017491A1 (en) | 2000-09-14 | 2003-01-23 | Zuo-Rong Shi | Chromogenic in situ hybridization methods, kits, and compositions |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| JP2004513660A (ja) * | 2000-11-22 | 2004-05-13 | トリリウム セラピューティクス インコーポレーティッド | 切断型ｃｄ２００ |
| CZ306180B6 (cs) | 2000-12-07 | 2016-09-14 | Eli Lilly And Company | GLP-1 fúzní proteiny |
| US20040198661A1 (en) | 2000-12-08 | 2004-10-07 | Bowdish Katherine S. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US7427665B2 (en) | 2000-12-08 | 2008-09-23 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line |
| WO2002069232A2 (en) | 2001-02-19 | 2002-09-06 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity |
| US6590059B2 (en) | 2001-05-11 | 2003-07-08 | Ap Pharma, Inc. | Bioerodible polyorthoesters from dioxolane-based diketene acetals |
| US7368535B2 (en) | 2001-05-24 | 2008-05-06 | Trillium Therapeutics Inc. | CD200 receptors |
| US7306906B2 (en) | 2001-09-19 | 2007-12-11 | Alexion Pharmaceuticals, Inc. | Engineered templates and their use in single primer amplification |
| US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| WO2004060295A2 (en) | 2002-12-27 | 2004-07-22 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| CA2517519A1 (en) | 2003-03-04 | 2004-09-16 | Alexion Pharmaceuticals, Inc. | Vectors used to create hybrid constant regions |
| JP2007501021A (ja) * | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| CA2527726A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-cd3 antibody |
| EP1648511A1 (en) | 2003-07-29 | 2006-04-26 | Morphotek, Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| US6953417B2 (en) * | 2003-11-17 | 2005-10-11 | Borgwarner Inc. | Method for controlling a dual clutch transmission |
| WO2005074985A2 (en) * | 2004-02-02 | 2005-08-18 | Schering Corporation | Methods of modulating cd200 and cd200r |
| US8815235B2 (en) | 2004-06-02 | 2014-08-26 | Jan E. Schnitzer | Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2614766A1 (en) | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods of treating autoimmune disease using humanized anti-cd16a antibodies |
| DK1931709T3 (da) | 2005-10-03 | 2017-03-13 | Xencor Inc | Fc-varianter med optimerede fc-receptorbindingsegenskaber |
| NZ599035A (en) * | 2006-01-12 | 2013-12-20 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| EP2121015A4 (en) | 2007-01-11 | 2010-03-24 | Boehringer Ingelheim Int | CD200 AND ITS RECEIVER, CD200R, MODULE THE BONE MASS VIA THE DIFFERENTIATION OF OSTEOCLASTS |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
-
2007
- 2007-01-11 NZ NZ599035A patent/NZ599035A/en not_active IP Right Cessation
- 2007-01-11 MX MX2008009015A patent/MX2008009015A/es active IP Right Grant
- 2007-01-11 PL PL11005097T patent/PL2463305T3/pl unknown
- 2007-01-11 JP JP2008550399A patent/JP5404052B2/ja not_active Expired - Fee Related
- 2007-01-11 KR KR1020147016937A patent/KR20140091765A/ko not_active Application Discontinuation
- 2007-01-11 PT PT110050978T patent/PT2463305T/pt unknown
- 2007-01-11 SG SG10201400426XA patent/SG10201400426XA/en unknown
- 2007-01-11 TW TW096101216A patent/TW200804422A/zh unknown
- 2007-01-11 HU HUE11005097A patent/HUE028179T2/en unknown
- 2007-01-11 DK DK11005097.8T patent/DK2463305T3/da active
- 2007-01-11 US US12/087,683 patent/US8075884B2/en active Active
- 2007-01-11 ES ES11005097.8T patent/ES2586825T3/es active Active
- 2007-01-11 EP EP16163753.3A patent/EP3101033B1/en not_active Not-in-force
- 2007-01-11 NZ NZ569903A patent/NZ569903A/en not_active IP Right Cessation
- 2007-01-11 BR BRPI0707126-4A patent/BRPI0707126A2/pt not_active IP Right Cessation
- 2007-01-11 EP EP07716538A patent/EP1984403A2/en not_active Withdrawn
- 2007-01-11 EP EP11005097.8A patent/EP2463305B1/en not_active Not-in-force
- 2007-01-11 CA CA2636577A patent/CA2636577C/en not_active Expired - Fee Related
- 2007-01-11 KR KR1020087019334A patent/KR101459159B1/ko not_active IP Right Cessation
- 2007-01-11 ES ES16163753T patent/ES2709672T3/es active Active
- 2007-01-11 RU RU2008133032/10A patent/RU2520088C2/ru not_active IP Right Cessation
- 2007-01-11 SI SI200731817A patent/SI2463305T1/sl unknown
- 2007-01-11 CN CN201310627141.1A patent/CN103690947A/zh active Pending
- 2007-01-11 AU AU2007207764A patent/AU2007207764B2/en not_active Ceased
- 2007-01-11 SG SG10201400422QA patent/SG10201400422QA/en unknown
- 2007-01-11 WO PCT/US2007/000711 patent/WO2007084321A2/en active Application Filing
-
2008
- 2008-07-07 IL IL192668A patent/IL192668A/en not_active IP Right Cessation
-
2011
- 2011-12-06 US US13/311,910 patent/US8709415B2/en active Active
-
2012
- 2012-07-17 JP JP2012158564A patent/JP5911391B2/ja active Active
-
2013
- 2013-02-20 US US13/771,911 patent/US9000133B2/en active Active
- 2013-11-27 RU RU2013152730/10A patent/RU2013152730A/ru not_active Application Discontinuation
-
2014
- 2014-05-30 JP JP2014112056A patent/JP2014156487A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2463305T3 (da) | Antistoffer mod OX-2/CD200 og anvendelser deraf | |
| AU2021203876A1 (en) | Anti-CD3 antibodies, activatable anti-CD3 antibodies, multispecific anti-CD3 antibodies, multispecific activatable anti-CD3 antibodies, and methods of using the same | |
| KR102551269B1 (ko) | 저-점도 항원 결합 단백질 및 이의 제조 방법 | |
| CN111954680B (zh) | IL2Rβ/共同γ链抗体 | |
| CN110869389B (zh) | 抗ror1抗体及其制备和使用方法 | |
| DK2519543T3 (da) | Heterodimerbindende proteiner og anvendelse heraf | |
| KR102204937B1 (ko) | 글루코코르티코이드-유도 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도 | |
| TWI289668B (en) | Therapeutic human anti-IL-1R1 monoclonal antibody | |
| KR20210013156A (ko) | 항-cd33 항체, 항-cd33/항-cd3 이중특이성 항체, 및 이의 용도 | |
| KR20180081532A (ko) | 암 치료용 조성물 및 방법 | |
| TW200829271A (en) | Uses of anti-CTLA-4 antibodies | |
| KR20190122881A (ko) | 항-lag3 항체 및 항원-결합성 단편 | |
| TW200521141A (en) | Antibodies to M-CSF | |
| KR20220040483A (ko) | 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| TW200535144A (en) | Antibodies to madcam | |
| CZ20021760A3 (cs) | Použití anti-CTLA-4 protilátek | |
| KR20100041849A (ko) | Ｃｄ200에 대한 항체와 면역 반응의 저해에서 이들의 용도 | |
| KR20210123350A (ko) | 항-il2 수용체 감마 항원-결합 단백질 | |
| EA032830B1 (ru) | Антитела к pac1 человека и их применение для лечения головной боли | |
| CN110869392A (zh) | 用抗gitr激动性抗体治疗癌症 | |
| KR20230017841A (ko) | Cd3 항원 결합 도메인을 포함하는 단백질 및 이의 용도 | |
| TW202216743A (zh) | Ｉｌ－１０突變蛋白及其融合蛋白 | |
| CN111212658B (zh) | 双特异性抗体及其制备和使用方法 | |
| KR20220140802A (ko) | 항-acvr1 항체 및 이의 용도 | |
| CN114502151B (en) | Anti-CD 19 antibodies and methods of use and preparation thereof |